

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses

Citation for published version:

Wagstaffe, HR, Clutterbuck, EA, Bockstal, V, Stoop, JN, Luhn, K, Douoguih, M, Shukarev, G, Snape, MD, Pollard, AJ, Riley, E & Goodier, MR 2020, 'Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses', *Journal of Clinical Investigation*, vol. 130, no. 7, pp. 3936-3946. https://doi.org/10.1172/JCI132438

Digital Object Identifier (DOI):

10.1172/JCI132438

Link: Link to publication record in Edinburgh Research Explorer

Document Version: Publisher's PDF, also known as Version of record

Published In: Journal of Clinical Investigation

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





LSHTM Research Online

Wagstaffe, Helen R; Clutterbuck, Elizabeth A; Bockstal, Viki; Stoop, Jeroen N; Luhn, Kerstin; Douoguih, Macaya J; Shukarev, Georgi; Snape, Matthew D; Pollard, Andrew J; Riley, Eleanor M; +1 more... Goodier, Martin; (2020) Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses. Journal of Clinical Investigation. ISSN 0021-9738 DOI: https://doi.org/10.1172/JCI132438

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4656585/

DOI: https://doi.org/10.1172/JCI132438

Usage Guidelines:

 $Please \ refer \ to \ usage \ guidelines \ at \ https://researchonline.lshtm.ac.uk/policies.html \ or \ alternatively \ contact \ researchonline@lshtm.ac.uk.$

 $\label{eq:available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/$

1	Ebola Virus Glycoprotein Stimulates IL-18 Dependent Natural Killer Cell
2	Responses
3	
4	Helen R. Wagstaffe ^{1,†} , Elizabeth A. Clutterbuck ² , Viki Bockstal ³ , Jeroen N. Stoop ³ ,
5	Kerstin Luhn ³ , Macaya Douoguih ³ , Georgi Shukarev ³ , Matthew D. Snape ² , Andrew J.
6	Pollard ² , Eleanor M. Riley ^{1, 4} , <u>Martin R. Goodier^{1*}</u>
7	
8	¹ Department of Infection Biology, London School of Hygiene and Tropical Medicine,
9	London WC1E 7HT, U.K
10	² Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR
11	Oxford Biomedical Research Centre, Oxford, U.K
12	³ Janssen Vaccines and Prevention, Leiden, The Netherlands
13	⁴ Institute of Immunology and Infection Research, School of Biological Sciences,
14	University of Edinburgh, Edinburgh EH9 3FL, United Kingdom.
15	[†] Current: Immunobiology Section, UCL Great Ormond Street Institute of Child Health,
16	London, U.K
17	
18	*Correspondence address
19	Dr. Martin R. Goodier, Department of Infection Biology, London School of Hygiene and
20	Tropical Medicine, London WC1E 7HT, United Kingdom. Phone: +44 (0)20 7927 7934;
21	Email: martin.goodier@lshtm.ac.uk
22	

23 **Conflict of interest statement**

24 VB, JNS, KL, MD, GS are employees and potential stockholders of Janssen 25 Pharmaceuticals Inc. AJP chairs the UK Department of Health and Social Care's 26 (DHCSC) Joint Committee on Vaccination and Immunisation and the EMA Scientific 27 Advisory Group on vaccines, and he is a member of WHO's Strategic Advisory Group 28 of Experts. The views expressed in the publication are those of the author(s) and not 29 necessarily those of the DHSC, NIHR or WHO. MDS acts as an Investigator on behalf of the University of Oxford on clinical research studies funded by vaccine 30 31 manufacturers including Janssen, Pfizer, GlaxoSmithKline, Novavax, Medimmune and MCM. He receives no personal financial benefit for this work. 32

33

A Creative Commons CC-BY license is required in order to support publication feesfor this manuscript.

36 Abstract

37 Background

38 NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells;
39 these functions are enhanced during secondary immune responses and after
40 vaccination by synergy with effector T cells and virus-specific antibodies. In human
41 Ebola virus infection, clinical outcome is strongly associated with the initial innate
42 cytokine response, but the role of NK cells has not been thoroughly examined.

43 Methods

The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 studies. Here, we analysed NK cell phenotype and function in response to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen, and in response to in vitro Ebola glycoprotein stimulation of PBMC isolated before and after vaccination.

50 Results

51 We show enhanced NK cell proliferation and activation after vaccination compared 52 with baseline. Ebola glycoprotein-induced activation of NK cells was dependent on 53 accessory cells and TLR-4-dependent innate cytokine secretion (predominantly from 54 CD14⁺ monocytes) and enriched within less differentiated NK cell subsets. Optimal 55 NK cell responses were dependent on IL-18 and IL-12, whilst IFN-γ secretion was 56 restricted by high concentrations of IL-10.

57 Conclusion

- 58 This study demonstrates the induction of NK cell effector functions early after 59 Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation 60 and regulation of NK cells by Ebola GP.
- 61 Trial registration
- 62 ClinicalTrials.gov Identifier: NCT02313077
- 63 Funding
- U.K. Medical Research Council Studentship in Vaccine Research, Innovative
 Medicines Initiative 2 Joint Undertaking, EBOVAC (Grant 115861) and Crucell Holland
 (now Janssen Vaccines & Prevention B.V.), European Union's Horizon 2020 research
 and innovation programme and European Federation of Pharmaceutical Industries
 and Associations (EFPIA).

69 Introduction

70 Ebola virus infection causes a rapid onset, severe acute haemorrhagic fever (Ebola 71 virus disease, EVD) with mortality ranging from 25% to 90% depending on the 72 outbreak (1). Clinical development of effective vaccines remains a high priority as 73 regular disease outbreaks continue on the African continent, and there is still no 74 licensed product. Ebola vaccine development has focused on the viral glycoprotein 75 (GP), the only protein exposed on the surface of the mature virus particle; Ebola virus 76 GP is essential for viral entry into host cells and is highly immunogenic (2, 3). Studies 77 of a GP expressing recombinant vesicular stomatitis virus (rVSV) vaccine have shown 78 that immunity directed against this protein confers protection (4). A 2-dose vaccination 79 approach with adenovirus type 26 expressing the Zaire Ebola virus GP (Ad26.ZEBOV) 80 and modified vaccinia Ankara expressing ZEBOV, Sudan Ebola virus and Marburg 81 virus GP and Tai Forest Ebola virus nucleoprotein (MVA-BN-Filo), has been shown to be safe and immunogenic in phase 1 clinical trials, eliciting robust and persistent 82 83 antibody concentrations and antigen specific T cell responses (5-9). The 84 Ad26.ZEBOV, MVA-BN-Filo vaccine regimen is currently being evaluated in Phase 2 85 and 3 clinical studies.

Innate immune dysregulation underlies the pathophysiology of EVD resulting in failure 86 to activate essential effector cell functions and consequent uncontrolled virus 87 88 replication, systemic virus dissemination and inflammation (2, 10). Ebola virus infects 89 macrophages and DCs impairing maturation and the type I IFN response due in part 90 to the presence of interferon inhibiting domains (IIDs) within viral proteins, VP24 and 91 VP35. In vitro studies with human peripheral blood mononuclear cells (PBMC) have 92 shown that DC maturation, type I IFN secretion and NK cell activation are all enhanced 93 when these Ebola virus IIDs are mutated (11, 12). Impairment of the type I IFN

94 response is accompanied by an excessive pro-inflammatory cytokine response (2, 13). 95 In vitro studies have shown that the Ebola virus GP is a potent ligand for TLR-4 and 96 induces activation of non-infected monocytic cell lines, monocyte-derived DCs and 97 macrophages to produce cytokines (14-18). Importantly, an initial type I IFN response 98 accompanied by modest and transient IL-1 β and TNF- α secretion correlated with 99 survival among EVD patients, whereas high IL-10 was associated with fatal outcome 100 (13, 19, 20). This indicates that the earliest interactions between the Ebola virus and 101 the host immune system are critical for determining the outcome of infection.

102 Non-clinical studies have suggested that, if they can be appropriately activated, NK 103 cells may potentially play a role in vaccine-induced protection from EVD. For example, 104 murine infection with Ebola virus fails to induce an NK cell response, whereas 105 treatment of mice with Ebola GP virus-like particles (VLPs) confers complete 106 protection against a lethal Ebola virus infection just 3 days later; this protection was 107 lacking after in vivo NK cell ablation (10). Furthermore, NK cell cytotoxicity and IFN-y 108 secretion have been implicated in the prolonged survival of NK cell-sufficient mice 109 immunised with the rVSV-vectored Ebola virus GP vaccine compared with NK cell-110 depleted mice (21). In humans, upregulation of the activation markers NKG2D and 111 CD38 on NK cells was noted within 24 hours of vaccination with the rVSV-ZEBOV 112 vaccine (22). When taken together with evidence from non-human primates of partial 113 protection against live virus within 3 days of vaccination and full protection within 7 114 days, this suggests that NK cells may be able to mediate rapid and effective protection 115 against Ebola virus (4, 23). Moreover, after vaccination, NK cells may synergise with 116 anti-GP antibodies to clear virus-infected cells via antibody-dependent cellular 117 cytotoxicity (ADCC) (24, 25).

118 Here, we evaluate the effect of the 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination 119 regimen on accessory cell cytokine secretion, NK cell phenotype and NK cell effector 120 function both ex vivo and in response to restimulation in vitro with soluble Ebola virus 121 GP (EBOV GP). We find that vaccination with Ad26.ZEBOV, MVA-BN-Filo induces 122 proliferation and activation of less differentiated NK cell subsets as measured ex vivo. 123 We also find that stimulation of PBMC (collected either before or after vaccination) 124 with EBOV GP induces TLR-4 dependent secretion of high concentrations of 125 inflammatory cytokines, mainly from CD14⁺ monocytes and accessory cell-dependent 126 NK cell activation. EBOV GP induced NK cell activation was inhibited by neutralising 127 antibodies to IL-18 (and IL-12) and was enhanced by IL-10 receptor blockade. These 128 studies further our understanding of innate immune responses to Ebola virus GP 129 stimulation and suggest NK cells could potentially play a role in early Ad26.ZEBOV, 130 MVA-BN-Filo vaccine regimen-induced immune responses.

131 Results

Robust NK cell responses to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen measured ex vivo.

134 Vaccination with several anti-viral vaccines, including influenza, has been shown to 135 promote NK cell activation and a realignment of subsets associated with functional 136 differentiation (26-28). We therefore analysed the effect of Ad26.ZEBOV, MVA-BN-137 Filo vaccination on NK cell activation and subset distribution. Ex vivo flow cytometric analysis of CD56⁺CD3⁻ NK cells from pre-vaccination (visit 0), post-dose 1 (visit 1) and 138 139 post-dose 2 (visit 2) samples was performed. NK cells were divided into CD56^{bright}, 140 CD56^{dim}CD57⁻ and CD56^{dim}CD57⁺ (or total CD56^{dim}) subsets (CD56^{bright} representing 141 the least differentiated and CD56^{dim}CD57⁺ the most differentiated subset) (29). The 142 expression of Ki67 (a cell cycle marker of proliferation), IL-2Rα-chain (CD25, a 143 component of the IL-2R complex and marker of activation) and NK cell receptors 144 NKG2A and NKG2C was analysed for each subset (the flow cytometry gating 145 strategies are shown in Supplementary Figure 1a). Initially, samples from all five 146 vaccination groups (groups 1 and 2; MVA-BN-Filo on day 1 and Ad26.ZEBOV on 147 either day 29 or 57 respectively, groups 3, 4 and 5; Ad26.ZEBOV on day 1 and MVA-148 BN-Filo on days 29, 57 or 15 respectively) were pooled for analysis.

When data for all vaccination groups were combined, there was a significant increase in the representation of CD56^{bright} NK cells within total NK cells and a corresponding decrease in the frequency of CD56^{dim} NK cells across vaccination visits (Figure 1a). CD56^{bright} NK cells had the highest intrinsic capacity to proliferate, reflected in the higher percentage expression of Ki67 in this subset (Figure 1b), followed by CD56^{dim}CD57⁻ cells. There was a significant increase in the frequency of CD56^{bright}

Ki67⁺ and CD56^{dim}CD57⁻ Ki67⁺ NK cells between visit 1 and visit 2, suggesting that
proliferation of less differentiated NK cells may explain their increasing frequency (as
in Figure 1a). There was no significant change in the proportion of more highly
differentiated (CD56^{dim}CD57⁺) NK cells expressing Ki67 (Figure 1b).

159 Consistent with the expression of the inhibitory receptor NKG2A on less differentiated 160 NK cell subsets, a significant increase in frequency of NK cells expressing NKG2A 161 was observed at visit 2, with no significant change in expression of the corresponding 162 activating receptor, NKG2C (Figure 1c). There was a small but significant increase 163 between visits 1 and 2 in the percentage of CD56^{dim} (but not CD56^{bright}) NK cells 164 expressing CD25 (median 0.73% at visit 1; 0.86% at visit 2) (Figure 1d). The proportion 165 of CD25⁺ NK cells was positively correlated with the frequency of proliferating (Ki67⁺) 166 NK cells 21 days post-dose 2, further suggesting an association between NK cell 167 activation and proliferation in response to vaccination (Figure 1e). No effect of 168 vaccination was observed on the percentage or mean fluorescence intensity (MFI) of 169 NK cells expressing CD16 (the low affinity IgG receptor III, FcyRIII) (Supplementary 170 Figure 1b). These data indicate proliferation of less differentiated NK cells in response 171 to Ad26.ZEBOV, MVA-BN-Filo vaccination.

172 Overall, no significant changes in ex vivo NK cell phenotype and function were 173 observed after the primary vaccination but significant NK cell proliferation and CD25 174 expression were observed after the secondary vaccination but with a diversity of 175 responses among individuals. To investigate any effects of the order and/or interval of 176 the 2 doses, NK cell responses were reanalysed by vaccination group. Increasing CD56^{bright} and decreasing CD56^{dim} NK cell frequencies after vaccination was indicated 177 178 by a trend in all groups except group 4 (Ad26.ZEBOV followed by MVA-BN-Filo at day 179 57) and reached significance by one-way ANOVA across vaccination visits in groups

3 and 5 only (Ad26.ZEBOV followed by MVA-BN-Filo at day 29 and 15 respectively)
(Supplementary Figure 2a, b). Furthermore, there was a significant increase in
CD56^{bright} Ki67⁺ and CD56^{dim} CD25⁺ NK cells between baseline and post-dose 2 in
group 4 only (Supplementary Figure 2c, d). These data suggest that the Ad26.ZEBOV,
MVA-BN-Filo vaccine regimen induced a more robust NK cell response than MVA-BNFilo, Ad26.ZEBOV regimen. However, these effects were small and this subgroup
analysis may lack statistical power due to small numbers of participants.

187

188 NK cell CD107a and CD25, but not IFN-γ upregulation in response to EBOV GP 189 stimulation in vitro.

190 To determine the effect of Ad26.ZEBOV, MVA-BN-Filo vaccination regimen on NK cell 191 responses to soluble EBOV GP, baseline, visit 1 and visit 2 PBMCs were cultured for 192 8 and 18 hours with 10µg/ml EBOV GP. Frequencies of NK cells expressing CD107a 193 and IFN-y (at 8 hours) or CD25 and CD16 (at 18 hours) were analysed by flow 194 cytometry (gating strategies are shown in Figure 2a). There were no significant 195 differences in response to EBOV GP between vaccination groups (Supplementary 196 Figure 2e-g), therefore, all five vaccination groups were combined for analysis. In vitro 197 stimulation with EBOV GP induced a significant increase in the proportion of NK cells 198 expressing CD107a (Figure 2b) and CD25 (Figure 2c) at the cell surface compared 199 with unstimulated cultures (medium alone). EBOV GP stimulation had no effect on NK 200 cell IFN-y (at 8 or 18 hours) or CD16 expression (Figure 2d, e). The effect of EBOV 201 GP on markers of NK cell function did not differ across vaccination visits (Figure 2b-e) 202 suggesting the effect of EBOV GP on NK cells is independent of vaccine-induced T 203 cell and antibody responses.

204 Given that there was no effect of vaccination on the NK response to EBOV GP, the 205 analysis of NK cell function by differentiation subset was restricted to the baseline data 206 set (Figure 3). This analysis revealed that IFN-y secretion was restricted to the less 207 differentiated CD56^{bright} and CD56^{dim}CD57⁻ subsets and that significant induction of IFN-y by EBOV GP was detected only within the CD56^{dim}CD57⁻ subset (Figure 3a). 208 209 By contrast, CD107a and CD25 upregulation in response to EBOV GP was seen in all 210 NK cell subsets (Figure 3b, c), with a significantly higher CD25 expression in the CD56^{bright} subset compared with CD56^{dim} subsets (Figure 3c). The majority of CD25⁺ 211 212 NK cell events were CD56^{dim}CD57⁻ (60.5%) (Figure 3d). Overall, these data 213 demonstrate that EBOV GP induces markers associated with NK cell cytotoxicity 214 (CD107a) and activation (CD25), with a much lesser impact on IFN-y secretion, and 215 that these responses are not enhanced by vaccination.

216

217 High concentrations of inflammatory cytokines induced by EBOV GP in vitro.

218 NK cells are able to respond to cytokines secreted from activated accessory cells in 219 response to viral stimuli. To quantify cytokine production in response to EBOV GP 220 stimulation, baseline and 21-day post-dose 2 vaccination PBMC samples were stimulated with EBOV GP in vitro for 18 hours and cytokine concentrations in cell 221 222 supernatants were measured by Luminex. EBOV GP induced secretion of high 223 concentrations of IL-10, IL-1 β , IFN- α 2, GM-CSF, TNF- α and IFN- γ from PBMCs at 224 baseline and post-dose 2 samples compared with medium alone, where minimal 225 concentrations were observed (Figure 4). Particularly high concentrations of IL-10 (median 3142pg/ml at baseline), IL-1ß (median 1299pg/ml at baseline), GM-CSF 226 227 (median 465pg/ml at baseline) and TNF- α (median 5480pg/ml at baseline) were

measured in response to EBOV GP (Figure 4a, b, d, e). IFN-α2 secretion was also significantly enhanced by EBOV GP however the absolute concentrations of this cytokine were low (median 6.1pg/ml at baseline) compared with the other myeloid cell-derived cytokines (Figure 4c). Similarly, a low concentration of IL-12(p70) (maximum 6.6pg/ml) was detectable by Luminex in only a small number of individuals (13 of 71 at baseline and 9 of 71 at post-dose 2; not shown). Conversely, there was no increase in IP-10 secretion over medium alone and IL-15 was not detected (not shown).

235 With the exception of a small but significant reduction in EBOV GP-induced TNF-a 236 concentration in cultures of post-dose 2 PBMCs (4555pg/ml post-dose 2; 5480pg/ml 237 at baseline) (Figure 4e), there was no overall effect of vaccination on cytokine 238 concentrations. When vaccination groups were analysed separately, concentrations 239 of GM-CSF in group 3, IFN- α 2 in group 4 and TNF- α in group 5 were significantly 240 reduced at visit 2 compared with baseline (Supplementary Figure 3c, d, e) suggesting 241 that reductions in cytokine responses were limited to Ad26.ZEBOV, MVA-BN-Filo 242 vaccine regimen. In summary, EBOV GP stimulated the release of high concentrations 243 of IL-10, IL-1β, GM-CSF and TNF-α from PBMCs, indicative of myeloid cell activation, 244 with lower concentrations of IFN- α 2, IL-12 and IFN- γ detected.

245

246 Myeloid accessory cell cytokine-dependent NK cell activation.

Vaccination independent activation of less differentiated, cytokine-responsive NK cell subsets accompanied by high levels of myeloid cell-derived cytokine secretion, led us to hypothesise that the NK cell response to EBOV GP is a function of indirect NK cell activation. To test this hypothesis, we compared IFN-γ, CD107a and CD25 expression in response to EBOV GP among PBMCs, purified NK cells and purified NK cells in the 252 presence of a 1:1 ratio of CD14⁺ monocyte-enriched cells from healthy (non-253 vaccinated) control subjects (Figure 5a-c). Expression of CD107a, IFN-y and CD25 in 254 the CD56^{bright} NK cell population (in which significant induction was measured) were 255 determined by flow cytometry as before. IFN-y, CD107a and CD25 expression was 256 significantly reduced in purified NK cells compared with whole PBMC suggesting that 257 accessory cell-derived stimuli are required for optimal NK cell responses to EBOV GP 258 (Figure 5a-c). CD107a and CD25 responses were recovered in all individuals after 259 adding back the enriched CD14⁺ monocyte fraction (Figure 5b-c), suggesting this 260 population of cells supports NK cell function after EBOV GP stimulation; NK cell IFN-261 y expression was not consistently recovered after adding back CD14⁺ cells (Figure 262 5a).

263 To determine the precise nature of the accessory cell-dependent stimuli that drive NK 264 cell responses to EBOV GP, whole PBMCs from (non-vaccinated) control subjects 265 were stimulated with EBOV GP in the presence of neutralising antibodies to IL-2, IL-266 12, IL-15, IL-18 and IFN- $\alpha\beta$ R2. The blockade of IL-18 significantly reduced the 267 frequency and MFI of NK cell CD25 expression (Figure 5d, e, Supplementary Figure 268 4a), with blockade of IL-12 also significantly reducing CD25 expression within the 269 CD56^{bright} NK cell subset (Figure 5f, g). CD107a expression was also impaired by IL-18 blockade, reflected in the CD56^{bright} and CD56^{dim}CD57⁻ subsets (Figure 5h, 270 271 Supplementary Figure 4a). There was no effect of IL-12 or IL-18 blockade on NK cell 272 IFN-y expression (Figure 5i, Supplementary Figure 4a). Conversely, neutralisation of 273 IL-2 or IL-15, or IFN-αβR2 blockade, had no significant effect on NK cell activation in 274 any NK cell subset (not shown). In summary, these data suggest optimal NK cell CD25 275 and CD107a expression in response to EBOV GP stimulation is dependent on myeloid 276 cell-derived IL-18 and IL-12.

277 As both IL-12 and IL-18 were not amenable to detection by Luminex assay of cell 278 culture supernatants, we next sought to measure these responses to EBOV GP using 279 high sensitivity ELISA for secreted IL-18 and flow cytometry for intracellular IL-12 280 (gating strategy shown in Supplementary Figure 5a). There was a significant increase 281 in IL-18 measured in supernatant after 18 hours stimulation with EBOV GP (median 282 47.6pg/ml, range 16.8-183.5pg/ml) (Figure 5j), which correlated significantly with 283 increasing NK cell CD25 expression (Figure 5k). We were able to detect IL-12(p40)⁺ 284 cells by flow cytometry with significantly higher frequencies of IL-12(p40)⁺ cells in 285 CD14⁻CD11c⁺ myeloid DCs (mDC) (30), total CD14⁻ cells and CD14⁺ monocytes 286 compared with medium alone. The highest frequencies of IL-12(p40)⁺ cells were 287 observed in the CD14⁺ monocyte population (0.22%) (Figure 5L), consistent with the 288 recovery of NK cell CD107a and CD25 responses by purified NK cells in the presence 289 of this cell population.

290

291 **Regulation of NK cell IFN-γ production by EBOV GP induced IL-10.**

292 IL-10 is an essential immunoregulatory cytokine that is typically upregulated in 293 response to inflammation (31). Having detected very high concentrations of IL-10 in 294 supernatants of EBOV GP-stimulated PBMCs (Figure 4a) we explored the relationship 295 between IL-10 production and NK cell function. NK cell IFN-y expression significantly 296 negatively correlated with IL-10 secretion in 18-hour cultures in both baseline (r=-297 0.331, p=0.0218) (Figure 6a) and 21-day post-dose 2 PBMC (r=-0.324, p=0.0157; not 298 shown) suggesting that IL-10 induced by EBOV GP might restrict the NK cell IFN-y 299 response. Therefore, PBMC from (non-vaccinated) control subjects were cultured for 300 18 hours with EBOV GP in the presence of a blocking monoclonal antibody to the IL-

301 10 receptor (IL-10R) or the appropriate isotype control antibody. IL-10R blockade 302 resulted in significantly higher frequencies of IFN-y⁺ (Figure 6b) and CD25⁺ (Figure 303 6c) NK cells (and a significant increase in CD25 MFI; median 349.5 with IL-10R 304 blockade; 110.5 with isotype control; p=0.0002; not shown) compared with isotype 305 control treated cultures. CD107a was significantly enhanced by IL-10R blockade in the 306 CD56^{dim}CD57⁺ NK cell subset only (Supplementary Figure 4b), and IL-10R blockade particularly enhanced IFN-y responses in CD56^{bright} and CD56^{dim}CD57⁻ NK cell 307 308 populations (Supplementary Figure 4b).

309 We also investigated whether serum components, such as IL-18 binding proteins, may 310 restrict IL-18-dependent responses to EBOV GP in some individuals. Overall, in vitro 311 NK cell responses to EBOV GP were minimally affected by high concentrations of pre 312 or post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum (up to concentrations of 25% 313 v/v) except CD25 expression was partially inhibited in the CD56^{bright} NK cell population 314 (Supplementary Figure 6a-d). In contrast, induction of CD25 by exogenous IL-18 was 315 almost fully inhibited in the presence of high concentrations of serum, consistent with a potential role for IL-18BP in limiting the activity of IL-18. However, NK cell activation 316 317 by a cocktail of IL-18 and IL-12 was only partially inhibited at high serum concentration 318 (Supplementary Figure 6f, g).

To determine the cellular source of the cytokines induced by EBOV GP, PBMC were cultured with EBOV GP for 18 hours, stained for intracellular IL-10, GM-CSF and TNFa and analysed by flow cytometry (gating strategy shown in Supplementary Figure 5a). IL-10 was expressed predominantly in CD14⁺ monocytes (median 6.0%) with little or no evidence of expression in B cells, mDCs, CD14⁻, NK cells or T cells (Figure 6e). Back-gating confirmed that the majority of IL-10⁺ cells were CD19⁻CD14⁺ monocytes (Figure 6f) which is consistent with the lack of recovery of IFN-y responses in purified

326 NK cells co-cultured with CD14⁺ monocytes (Figure 5a). GM-CSF expression was also 327 essentially restricted to monocytes whereas the frequencies of TNF- α was similar in 328 mDCs and monocytes (Supplementary Figure 5b, c). In summary, monocytes are the 329 predominant source of inflammatory cytokines in response to EBOV GP in primary peripheral blood and monocyte-derived IL-10 negatively regulates NK cell IFN-y 330 331 secretion and CD25 expression. This immediate, robust IL-10 response could 332 potentially explain the lack of IFN-y expression by NK cells in response to EBOV GP 333 both before and after vaccination (Figure 2).

334

335 **EBOV GP-induced NK cell activation is TLR-4 dependent.**

336 EBOV GP stimulates cytokine secretion in human monocytic cell lines and in vitro 337 generated monocyte-derived DCs and macrophages in a TLR-4-dependent fashion 338 (14-17). TLR-4 is expressed at high levels on human peripheral blood monocytes, as 339 well as other myeloid lineage cells including macrophages and granulocytes (32). We 340 therefore assessed the effect of blocking TLR-4 on cytokine secretion (measured by 341 Luminex) and NK cell activation (by flow cytometry) in response to EBOV GP within 342 PBMC from (non-vaccinated) control subjects. TLR-4 blockade significantly reduced 343 secretion of IL-10 (0.3 fold-reduction; 7 of 7 donors) (Figure 7a), IL-1β, GM-CSF and 344 IFN-y but had no overall effect on IFN- α 2 or TNF- α secretion (Figure 7b). Parallel 345 effects were observed among NK cells where there was a partial, but significant, 346 decrease in frequencies of IFN- γ^+ (median 49.6% decrease in frequency) and CD25⁺ 347 (median 14.6% decrease in frequency) CD56^{bright} NK cells in the presence of TLR-4 348 blocking antibodies (Figure 7c, d). Overall, these data indicate that NK cell activation

- 349 by EBOV GP is mediated, at least in part, via ligation of TLR-4 on primary human
- 350 monocytes and the induction of cytokines.

351 Discussion

352 In the 2014-2016 Ebola virus outbreak in West Africa, almost 30,000 cases of EVD 353 were reported with more than 11,000 deaths (33). In 2019, Ebola virus continues to 354 be a considerable global health concern, with the second largest outbreak on record 355 currently ongoing in the Democratic Republic of the Congo (34). Detailed 356 understanding of the immune response to Ebola virus infection and mechanisms of 357 protection induced by Ebola virus vaccines would assist in efforts of prevention and 358 containment of future outbreaks. We analysed the effect of the heterologous 2-dose 359 Ad26.ZEBOV, MVA-BN-Filo vaccine regimen on human NK cell phenotype ex vivo 360 and primary human innate cell function in response to soluble EBOV GP in vitro. We 361 demonstrate NK cell activation, proliferation and expansion of less differentiated NK 362 cells and found that, independently of vaccination, CD14⁺ monocytes are key 363 responders to Ebola virus GP, rapidly producing a range of inflammatory cytokines in 364 a manner that is partially dependent on TLR-4. Subsequent NK cell activation and 365 function, dependent on myeloid cell-derived IL-12 and IL-18, was almost completely 366 abrogated by the very high levels of IL-10 secreted as part of the acute myeloid cell 367 response to EBOV GP in vitro.

Activation and proliferation of NK cells after vaccination has been demonstrated with 368 both inactivated and live attenuated vaccines. Jost et al demonstrated upregulation of 369 370 CD69 and CD25 and increased numbers of CD56^{bright} NK cells at day 4 post-influenza 371 vaccination (26) and Marguardt et al. observed heightened NK cell Ki67 expression 372 (peaking at day 10) after yellow fever vaccination (27). We have previously 373 demonstrated increased percentages and proliferation of CD56^{bright} NK cells at day 3 374 and up to 4 weeks after influenza vaccination (28). Our ex vivo data demonstrate 375 activation of less differentiated NK cells by a vectored, Ebola GP-expressing vaccine.

We detected heightened CD56^{bright} NK cell proliferation up to 78 days after first vaccination (21 days post-dose 2) and an increase in the proportion of CD56^{bright} NK cells from as early as day 15 post-dose 1 until at least 21 days post-dose 2. Increased expression of CD25 by NK cells post-vaccination may indicate the potential for T cell derived IL-2 to contribute to NK cell proliferation and activation (28, 35, 36).

381 The pathogenesis of EVD is closely linked to the very high levels of pro-inflammatory 382 cytokines induced by the infection (13, 19, 20). We show for the first time within primary 383 human PBMC cultures, that Ebola GP stimulated the secretion of high levels of IL-1 β , 384 GM-CSF and TNF-α independently of vaccination. This inflammatory response was 385 accompanied by an equally rapid and potent IL-10 response and somewhat lower 386 levels of IL-12, IL-18 and IFN-α2. These data - in a highly relevant ex vivo system -387 corroborate previous observations from human cell lines and in vitro generated 388 monocyte-derived DCs and macrophages (11, 14, 16, 18). The relatively low levels of 389 NK cell and T cell-activating cytokines together with the abundance of IL-10 suggest 390 the generation of a tightly regulated cytokine environment within hours of exposure to 391 soluble EBOV GP. Rapid production of IL-10 in response to a potent pro-inflammatory 392 stimulus is a well-described feature of the human homeostatic response; in preventing 393 a life-threatening cytokine storm, this can also influence the emerging adaptive 394 response (31). Indeed, pro and anti-inflammatory cytokines both indirectly correlate 395 with survival after EVD indicating that IL-10 itself, although associated with anti-396 inflammatory properties does not predict protection from disease (13).

Innate, pro-inflammatory cytokine responses are also regulated by specific cytokinebinding serum proteins, including IL-18 binding protein (IL-18bBP) (37). We observed
that high concentrations (up to 25% v/v) of serum (pre- or post-vaccination) inhibited
the NK cell CD25 response to rIL-18 (as expected) but had rather little effect on the

401 response to cytokine cocktails (e.g. rlL-18 plus rlL-12) or EBOV GP suggesting that 402 while IL-18BP may limit the effects of IL-18 it may have less impact on the much lower, 403 synergistic, combinations of cytokines induced by, for example, a viral infection or on 404 the cell-contact mediated events at the NK cell-monocyte synapse. Additionally, our 405 data demonstrate reduction of CD25 and degranulation responses in post-dose 2 vaccination serum compared with pre-vaccination serum in some individual vaccinees, 406 407 consistent with a potential role for vaccine-induced antibody in blocking EBOV GP-408 TLR-4 interactions at higher serum concentrations.

409 CD14⁺ monocytes were the main source of both inflammatory and anti-inflammatory 410 cytokines within hours of EBOV GP stimulation. Both types of monocyte response and 411 the downstream NK cell response were TLR-4-dependent confirming prior studies 412 showing Ebola virus GP is recognised by TLR-4 inducing inflammatory cytokine 413 secretion (14, 16, 17, 38). We demonstrate indirect, innate cytokine-dependent NK 414 cell effector function in response to Ebola virus GP in human PBMC in vitro culture. 415 independent of prior Ad26.ZEBOV, MVA-BN-Filo vaccination. IL-18 and to a lesser 416 extent, IL-12, from myeloid accessory cells were required for optimal NK cell 417 degranulation and CD25 upregulation. This innate response, which is particularly 418 enriched in less differentiated NK cell subsets, is consistent with the proliferation and 419 activation of the least differentiated, CD56^{bright} NK cells after vaccination itself 420 (measured ex vivo). This suggests that, as seen in vitro, expression of Ebola GP by 421 vaccination could potentially stimulate innate, cytokine-dependent NK cell activation 422 in vivo.

423 Innate NK cell activation in response to EBOV GP, with an apparent lack of 424 enhancement of NK cell responses post-vaccination, is in complete contrast to 425 previous observations with yellow fever, BCG and influenza vaccination (27, 28, 39).

426 It is well established that enhanced NK cell responses after vaccination, are mediated 427 in part by IL-2 from antigen-specific T cells and vaccine induced antibody (27, 28, 35, 428 39-41). Despite evidence of moderate induction of IL-2⁺IFN- γ ⁺TNF- α ⁺ triple positive T 429 cells and the presence of 1% post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum (5), 430 there was no enhancement of the NK cell response, or downregulation of CD16 in 431 response to EBOV GP post-vaccination compared with baseline. Plausibly, the lack of 432 post-vaccination NK cell enhancement in vitro may be linked to the effects of 433 monocyte-derived IL-10. A system-wide analysis of the immune response to the rVSV-434 ZEBOV Ebola vaccine suggested negative regulation by inflammatory monocytes 435 (22), additionally, IL-10 blockade restored antigen-specific T cell-derived IL-2-436 dependent activation of NK cells in other viral infection models (42, 43).

In summary, we have characterised the NK cell response to the novel 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen. We also demonstrate that the robust TLR-4-dependent, monocyte-derived, innate cytokine response to Ebola GP both stimulates and regulates the NK cell effector response. This study contributes to our understanding of immune responses induced by Ebola vaccines and demonstrates that innate cytokine responses induced by Ebola GP may be integral to the induction and regulation of NK cell function after vaccination.

444 Materials and Methods

445 Study participants and samples

446 Cryopreserved PBMCs (with corresponding serum samples) from healthy adults, aged 447 18 to 50 years (median 39 years), were obtained from participants enrolled in the 448 EBL1001 single-centre, randomised, placebo-controlled, observer blind trial 449 conducted in Oxford, U.K. as described (ClinicalTrials.gov Identifier: NCT02313077) 450 (5). Participants were randomised into four groups, with a fifth group subsequently 451 added by a protocol amendment, to receive the Ad26.ZEBOV, MVA-BN-Filo vaccine 452 according to one of five vaccination schedules (Table 1). The vaccine comprises 453 monovalent Ad26.ZEBOV expressing the GP of the Ebola Zaire virus (Mayinga 454 variant) (Janssen Vaccines and Prevention B.V., The Netherlands) and multivalent 455 MVA-BN-Filo expressing the GP of the Sudan and Zaire Ebola viruses and Marburg 456 virus together with Tai Forest virus nucleoprotein (Bavarian Nordic, Denmark). Groups 457 1 and 2 received MVA-BN-Filo on day 1 and Ad26.ZEBOV on either day 29 or 57 458 respectively; groups 3, 4 and 5 received Ad26.ZEBOV on day 1 and MVA-BN-Filo on 459 days 29, 57 or 15 respectively.

460 Samples from 70 donors (non-placebo arms) were obtained from pre-vaccination 461 (baseline, visit 0), post-dose 1 (day 29, 57 or 15 depending on group; visit 1) and 21 462 days post-dose 2 (day 50, 78 or 36 depending on group; visit 2) (Table 1). Human 463 cytomegalovirus (HCMV) serology was conducted on the baseline serum sample of 464 each donor by HCMV IgG ELISA (Demeditec, Kassel, Germany); 26 of 70 volunteers 465 (37%) were HCMV seropositive, 44 were HCMV seronegative and two were 466 indeterminate. Additional non-vaccinated, healthy, adult volunteers (n=16) were 467 recruited for subsequent in vitro experiments from among staff and students at the

468 London School of Hygiene and Tropical Medicine (LSHTM) using an anonymised469 volunteer database.

470 In vitro cellular assays

471 Cryopreserved PBMCs were thawed, washed in RPMI 1640 supplemented with 472 100U/ml penicillin/streptomycin and 20mM L-glutamine (Gibco, ThermoFisher) and 473 rested for 2 hours. The average cell yield after thaw was 5.8x10⁶ per vial (58%) 474 recovery). Fresh PBMC were isolated from heparinised whole blood using Histopague 475 1077 (Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. All cells were counted 476 using Fastread counting slides (ImmuneSystems, U.K.). Trial PBMC were stained 477 immediately ex vivo or cultured in 96-well round-bottom plates in RPMI 1640 478 supplemented as above and with 1% autologous (pre, post-dose 1 or post-dose 2) 479 serum and 10µg/ml purified recombinant Ebola virus GP (EBOV GP), Mayinga variant, 480 prepared in Hek293F cells (Janssen Vaccines and Prevention B.V.) for 8 and 18 hours 481 at 37°C.

482 For additional 18-hour experiments, fresh PBMC from non-trial donors were stimulated 483 with 10µg/ml EBOV GP or cytokines alone; IL-12; 5ng/ml (PeproTech, London, U.K.) 484 and/or IL-18; 10 or 50ng/ml (R&D Systems, Oxford, U.K.) in RPMI supplemented as 485 above and with 5% FCS, or 1, 5, or 25% pooled pre or post-vaccination serum. The 486 following blocking antibodies or isotype control antibodies were used, all at 3µg/ml; 487 anti-IL-2 (Becton Dickinson (BD) Biosciences, Oxford, U.K.), anti-IL-10R (Biolegend), 488 rat IgG2a isotype control (eBiosciences, ThermoFisher), anti-IL-12 (BD Biosciences), 489 anti-IL-15 (eBiosciences), anti-IL-18 (MBL, U.S.A), mouse IgG1 isotype control 490 (eBiosciences). Anti-IFN-αβR2 (Merck Millipore, Watford, U.K.) and mouse IgG2a 491 isotype control (eBiosciences) were used at a final concentration of 1µg/ml. In vitro

blockade of TLR-4 was performed in the presence of 5µg/ml anti-TLR-4 rabbit
polyclonal anti-sera or isotype matched control reagent with irrelevant specificity
(Invivogen, U.K.).

495 To determine accessory cell dependency, NK cells and CD14⁺ monocytes were 496 purified by magnetic bead separation (MACS) using NK Cell Isolation Kit (Miltenyi 497 Biotec, Germany) (NK cells 90.2%±3.2% pure) and Pan Monocyte Isolation Kit 498 (Miltenyi Biotec) (monocytes 62.8%±11% pure with less than 1% NK cell contamination), respectively. Cells were cultured as above for 18 hours in 5% FCS 499 500 (n=5). GolgiPlug (Brefeldin A; 1/1000 final concentration; BD Biosciences) and 501 GolgiStop (Monensin; 1/1500 concentration; BD Biosciences) were added to all in vitro cultures for the final 3 hours of culture. Cells were then stained with fluorophore 502 503 labelled antibodies for flow cytometry and culture supernatants were collected and 504 stored at -80°C for cytokine analysis by Luminex/ELISA.

505 Flow cytometry

506 Cells were stained for surface markers including a viability marker (Fixable Viability 507 Stain 700; BD Biosciences) in FACS buffer (PBS, 0.5% FCS, 0.05% sodium azide and 508 2mM EDTA) for 30 minutes in 96-well round bottom plates after blocking Fc receptors 509 for 5 minutes with Fc Receptor (FcR) Blocking Reagent (Miltenvi Biotec). Cells were 510 then washed in FACS buffer, fixed and permeabilised using Cytofix/Cytoperm Kit (BD 511 **Biosciences**) or Foxp3/Transcription Factor Fixation/Permeabilisation Kit 512 (eBiosciences) according to the manufacturer's instructions. Cells were then stained 513 for intracellular markers with FcR blocking for 20 minutes and washed again. Finally 514 cells were resuspended in FACS buffer and analysed using a BD LSRII flow 515 cytometer. Cells were acquired using FACSDiva software and data were analysed

using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates were set using
unstimulated cells or FMO controls. Samples with less than 100 NK cell events were
excluded from the analysis (<4% of samples evenly distributed across all groups).

519 The following fluorophore labelled antibodies were used: anti-CD3-V500 (clone 520 UCHT1) (BD Biosciences), anti-CD56-BV605 (clone HCD56), anti-IFN-y-BV785 521 (clone 4S.B3), anti-IFN-y-APC (clone 4S.B3), anti-CD25-BV785 (clone BC96), anti-522 CD11c-BV785 (clone 3.9), anti-CD14-AF700 (clone 63D3), anti-GM-CSF-PE-Dazzle 523 (clone BVD2-21C11), anti-TNF-α-FITC (clone MAb11), anti-IL-10-PE (clone JES3-524 9D7) (all Biolegend, London, U.K.). Anti-CD16-APC (clone CB16), anti-CD25-PerCPCy5.5 (clone BC96), anti-CD57-e450 (clone TB01), Ki67-PerCP-eFluor710 525 526 (clone 20Raj1), anti-CD19-PECy7 (clone HIB19), anti-IL-12-eFlour660 (clone C8.6) 527 (all eBiosciences), anti-NKG2A-PE-Vio770 (clone REA110) (Miltenyi Biotec), anti-528 NKG2C-PE (clone 134591) (R&D systems). Anti-CD107a-FITC (clone H4A3) (BD 529 Biosciences) was added to the culture at 2μ l per 100μ l for the whole culture period.

530 Luminex and IL-18 ELISA

531 Concentrations of GM-CSF, IFN- α 2, IFN- γ , TNF- α , IP-10, IL-1 β , IL-10, IL-12p70, IL-532 15 in cell culture supernatants were determined by Luminex technology (Merck 533 Millipore) using the xPONENT 4.1 software for data acquisition. The concentration of 534 IL-18 was determined by ELISA (R&D Systems).

535 Statistics

536 Statistical analysis was performed using GraphPad Prism version 7.04 (GraphPad, 537 California, U.S.A.). Functional responses were compared using Wilcoxon signed-rank 538 test or one-way ANOVA Friedman test with Dunn's correction for multiple 539 comparisons. For correlation analysis, a linear regression model was fitted in prism

and r and p values were determined using Spearman's correlation analysis.
Significance levels are assigned as *p, <0.05, **p, <0.01, ***p, <0.001, and ****p,
<0.0001 for all tests.

543 Study approval

544 Written informed consent was received from all participants prior to inclusion in the 545 study. The trial protocol and study documents were approved by the National 546 Research Ethics Service (reference number 14/SC/1408) and the LSHTM Research 547 Ethics Committee (reference number 14383).

548 Author contributions

549 HRW and MRG designed and performed the experiments, analysed data, and wrote 550 the manuscript. VB, JNS and KL participated in the analysis of data and advised on 551 the manuscript. MD and GS participated in the conception and design of the work 552 described and advised on the manuscript. AP and EAC were coinvestigators on the 553 above trial and advised on the manuscript. MDS was the Chief Investigator on the 554 phase 1 clinical trial of Ad26.ZEBOV, MVA-BN-Filo and advised on the manuscript. 555 EMR wrote and advised on the manuscript.

556 Acknowledgements

557 This work was supported by a U.K. Medical Research Council Studentship in Vaccine 558 Research (HRW). This project has received funding from the Innovative Medicines 559 Initiative 2 Joint Undertaking, EBOVAC (Grant 115861) and Crucell Holland (now Janssen Vaccines & Prevention B.V.). This Joint Undertaking receives support from 560 561 the European Union's Horizon 2020 research and innovation programme and 562 European Federation of Pharmaceutical Industries and Associations (EFPIA). AJP is 563 supported by the NIHR Oxford Biomedical Research Centre and is an NIHR Senior 564 Investigator. The views expressed in the publication are those of the author(s) and not 565 necessarily those of the NHS, the NIHR, MRC or European Union. MDS is supported 566 by the NIHR Oxford Biomedical Research Centre.

567 We also thank Carolynne Stanley for recruiting and obtaining consent from LSHTM 568 study subjects and for blood sample collection.

569 References

- 570 1. Weyer J, Grobbelaar A, and Blumberg L. Ebola virus disease: history, 571 epidemiology and outbreaks. *Current infectious disease reports*. 572 2015;17(5):480.
- 573 2. Ploquin A, Zhou Y, and Sullivan NJ. Ebola Immunity: Gaining a Winning
 574 Position in Lightning Chess. *Journal of immunology (Baltimore, Md : 1950).*575 2018;201(3):833-42.
- 576 3. Pavot V. Ebola virus vaccines: Where do we stand? *Clinical immunology* 577 (*Orlando, Fla*). 2016;173:44-9.
- Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ,
 Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in
 preventing Ebola virus disease: final results from the Guinea ring vaccination,
 open-label, cluster-randomised trial (Ebola Ca Suffit!). *Lancet (London, England).* 2017;389(10068):505-18.
- 583 5. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, et
 al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified
 Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. *Jama*.
 2016;315(15):1610-23.
- Shukarev G, Callendret B, Luhn K, and Douoguih M. A two-dose heterologous
 prime-boost vaccine regimen eliciting sustained immune responses to Ebola
 Zaire could support a preventive strategy for future outbreaks. *Hum Vaccin Immunother.* 2017;13(2):266-70.
- 591 7. Winslow RL, Milligan ID, Voysey M, Luhn K, Shukarev G, Douoguih M, et al.
 592 Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus
 593 Ankara-Vectored Ebola Vaccines at 1 Year. *Jama.* 2017;317(10):1075-7.

Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, et al.
 Randomized clinical trial examining safety and immunogenicity of heterologous
 prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data
 from Uganda and Tanzania. *The Journal of infectious diseases.* 2019.

- Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, et al.
 Randomized clinical trial examining safety and immunogenicity of heterologous
 prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data
 from Nairobi, Kenya. *The Journal of infectious diseases*. 2019.
- Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, et al.
 Role of natural killer cells in innate protection against lethal ebola virus infection. *The Journal of experimental medicine.* 2004;200(2):169-79.
- Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA, et al. The
 lack of maturation of Ebola virus-infected dendritic cells results from the
 cooperative effect of at least two viral domains. *Journal of virology.*2013;87(13):7471-85.
- Lubaki NM, Younan P, Santos RI, Meyer M, Iampietro M, Koup RA, et al. The
 Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated
 Immune Responses. *PLoS pathogens.* 2016;12(12):e1006031.
- Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, et
 al. Immune parameters and outcomes during Ebola virus disease. *JCI insight*.
 2019;4(1).
- 615 14. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, and Volchkov VE.
 616 Shed GP of Ebola virus triggers immune activation and increased vascular
 617 permeability. *PLoS pathogens.* 2014;10(11):e1004509.

- Lazaro-Frias A, Gomez-Medina S, Sanchez-Sampedro L, Ljungberg K, Ustav
 M, Liljestrom P, et al. Distinct Immunogenicity and Efficacy of Poxvirus-Based
 Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. *Journal of virology*. 2018;92(11).
- Lai CY, Strange DP, Wong TAS, Lehrer AT, and Verma S. Ebola Virus
 Glycoprotein Induces an Innate Immune Response In vivo via TLR4. *Frontiers in microbiology*. 2017;8:1571.
- 625 17. Okumura A, Pitha PM, Yoshimura A, and Harty RN. Interaction between Ebola
 626 virus glycoprotein and host toll-like receptor 4 leads to induction of
 627 proinflammatory cytokines and SOCS1. *Journal of virology.* 2010;84(1):27-33.
- Halfmann P, Hill-Batorski L, and Kawaoka Y. The Induction of IL-1beta
 Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection. *The Journal of infectious diseases.* 2018.
- Hutchinson KL, and Rollin PE. Cytokine and chemokine expression in humans
 infected with Sudan Ebola virus. *The Journal of infectious diseases*. 2007;196
 Suppl 2:S357-63.
- 634 20. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga
- 635 I, et al. Inflammatory responses in Ebola virus-infected patients. *Clinical and*636 *experimental immunology*. 2002;128(1):163-8.
- Williams KJ, Qiu X, Fernando L, Jones SM, and Alimonti JB. VSVDeltaG/EBOV
 GP-induced innate protection enhances natural killer cell activity to increase
 survival in a lethal mouse adapted Ebola virus infection. *Viral immunology.*2015;28(1):51-61.
- 641 22. Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, et al.
 642 Systems Vaccinology Identifies an Early Innate Immune Signature as a

643 Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. *Cell*644 *reports.* 2017;20(9):2251-61.

Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, et al.
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection
with the 2014/15 Ebola virus outbreak strain. *Science (New York, NY)*.
2015;349(6249):739-42.

- Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A Role
 for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection
 against Ebola Virus. *Cell host & microbe.* 2018;24(2):221-33.e5.
- Liu Q, Fan C, Li Q, Zhou S, Huang W, Wang L, et al. Antibody-dependentcellular-cytotoxicity-inducing antibodies significantly affect the post-exposure
 treatment of Ebola virus infection. *Scientific reports.* 2017;7:45552.
- 655 26. Jost S, Quillay H, Reardon J, Peterson E, Simmons RP, Parry BA, et al.
 656 Changes in cytokine levels and NK cell activation associated with influenza.
 657 *PloS one.* 2011;6(9):e25060.
- Marquardt N, Ivarsson MA, Blom K, Gonzalez VD, Braun M, Falconer K, et al.
 The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed
 by NK Cell Differentiation Independently of NK Cell Education. *Journal of immunology (Baltimore, Md : 1950).* 2015;195(7):3262-72.

Goodier MR, Rodriguez-Galan A, Lusa C, Nielsen CM, Darboe A, Moldoveanu
AL, et al. Influenza Vaccination Generates Cytokine-Induced Memory-like NK
Cells: Impact of Human Cytomegalovirus Infection. *Journal of immunology (Baltimore, Md : 1950).* 2016;197(1):313-25.


Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al.
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim

- 668 NK-cell differentiation uncoupled from NK-cell education. *Blood.*669 2010;116(19):3853-64.
- 670 30. Collin M, and Bigley V. Human dendritic cell subsets: an update. *Immunology.*671 2018;154(1):3-20.
- 672 31. Couper KN, Blount DG, and Riley EM. IL-10: the master regulator of immunity
 673 to infection. *Journal of immunology (Baltimore, Md : 1950).* 2008;180(9):5771674 7.
- 675 32. Vaure C, and Liu Y. A comparative review of toll-like receptor 4 expression and
 676 functionality in different animal species. *Frontiers in immunology*. 2014;5:316.
- 677 33. World Health Organisation W. Ebola Virus Disease Situation Report.
- 678 https://apps.who.int/iris/bitstream/handle/10665/208883/ebolasitrep_10Jun20
- 679 <u>16_eng.pdf;jsessionid=30DD3D5DD7229BFEDCE6CFB9B8299371?sequenc</u>
- 680 <u>e=1</u>. Accessed 16/08/2019, 2019.
- World Health Organisation W. Ebola virus disease Democratic Republic of the
 Congo. External situation report 51. <u>https://www.who.int/ebola/situation-</u>
 reports/drc-2018/en/. Accessed 16/08/2019, 2019.
- 684 35. Horowitz A, Behrens RH, Okell L, Fooks AR, and Riley EM. NK cells as
 685 effectors of acquired immune responses: effector CD4+ T cell-dependent
 686 activation of NK cells following vaccination. *Journal of immunology (Baltimore,*687 *Md : 1950).* 2010;185(5):2808-18.
- 688 36. Horowitz A, Hafalla JC, King E, Lusingu J, Dekker D, Leach A, et al. Antigen689 specific IL-2 secretion correlates with NK cell responses after immunization of
 690 Tanzanian children with the RTS,S/AS01 malaria vaccine. *Journal of*691 *immunology (Baltimore, Md : 1950).* 2012;188(10):5054-62.

Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A
novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive
decrease of free IL-18. *Cytokine*. 2001;14(6):334-42.

- Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, et al.
 Ebola virus exploits a monocyte differentiation program to promote its entry. *Journal of virology.* 2013;87(7):3801-14.
- 698 39. Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, et al. 699 Bacillus Calmette-Guerin (BCG) Revaccination of Adults with Latent 700 Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK 701 Responses. Journal of immunology (Baltimore, Cell Md : 1950). 702 2016;197(4):1100-10.
- 40. Darboe A, Danso E, Clarke E, Umesi A, Touray E, Wegmuller R, et al.
 Enhancement of cytokine-driven NK cell IFN-gamma production after
 vaccination of HCMV infected Africans. *European journal of immunology.*2017;47(6):1040-50.
- Goodier MR, Lusa C, Sherratt S, Rodriguez-Galan A, Behrens R, and Riley EM.
 Sustained Immune Complex-Mediated Reduction in CD16 Expression after
 Vaccination Regulates NK Cell Function. *Frontiers in immunology.* 2016;7:384.
- Porichis F, Hart MG, Massa A, Everett HL, Morou A, Richard J, et al. Immune
 Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. *Journal of immunology (Baltimore, Md : 1950).* 2018;201(3):971-81.
- Mandaric S, Walton SM, Rulicke T, Richter K, Girard-Madoux MJ, Clausen BE,
 et al. IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMVspecific CD4 T cells and prolonged MCMV persistence. *PLoS pathogens.*2012;8(8):e1002846.


718 Figures and legends



719

Figure 1. Robust NK cell responses to Ad26.ZEBOV, MVA-BN-Filo vaccinationmeasured ex vivo.

722 NK cell phenotype at baseline (visit 0), visit 1 (day 29, 57 or 15 post-dose 1) and visit 723 2 (21 days post-dose 2) was analysed ex vivo by flow cytometry (gating strategy is shown in Supplementary Figure 1), n=70. Frequencies of CD56^{bright} and CD56^{dim} (a), 724 725 CD56^{bright} Ki67⁺, CD56^{dim}CD57⁻ Ki67⁺ and CD56^{dim}CD57⁺ Ki67⁺ (b), NKG2A⁺ and 726 NKG2C⁺ (c), CD56^{bright} CD25⁺ and CD56^{dim} CD25⁺ NK cells (d) were determined. The 727 correlation between total NK cell CD25 and Ki67 expression at 21 days post-dose 2 728 (e) was also determined by Spearman's coefficient. Graphs show box and whisker plots with median, interguartile range (IQR) (box) and 10th-90th percentile (whiskers). 729 730 Comparisons across vaccination visits were performed using one-way ANOVA with 731 Dunn's correction for multiple comparisons. *p <0.05, **p <0.01, ***p <0.001.



733

Figure 2. NK cell CD107a and CD25, but not IFN-γ expression upregulation in
response to EBOV GP stimulation in vitro.

736 Whole PBMC from baseline (visit 0), visit 1 (day 29, 57 or 15 post-dose 1) and visit 2 737 (21 days post-dose 2) were stimulated with EBOV GP or left unstimulated (medium) 738 for 8 and 18 hours in the presence of 1% autologous serum, n=70. Cells were stained 739 for NK cell activation markers and analysed by flow cytometry. Frequencies of CD107a 740 and IFN-y, measured at 8 hours or CD25 and CD16 measured at 18 hours, within total 741 live CD3 CD56⁺ NK cells were gated using medium alone controls, plots shown from 742 one representative donor (a). Graphs show NK cell CD107a (b), IFN-y (c), CD25 (d) 743 and CD16 (d) expression as one point per donor with a line representing the median. 744 Comparisons across vaccination visits were performed using one-way ANOVA with 745 Dunn's correction for multiple comparisons and between conditions by Wilcoxon 746 signed-rank test. ****p < 0.0001.




Figure 3. Less differentiated NK cells respond strongly to EBOV GP stimulation invitro.

750 NK cell IFN-y (a) and CD107a (b), measured at 8 hours and CD25 (c), measured at 751 18 hours in response to medium alone and EBOV GP in baseline (visit 0) samples 752 only was analysed according to NK cell differentiation subset determined by CD56 and 753 expression (CD56^{bright}, CD56^{dim}CD57⁻, CD56^{dim}CD57^{intermediate (int)} CD57 and 754 CD56^{dim}CD57⁺), n=70. The proportion of CD25⁺ NK cell events per subset determined 755 by back-gating is also shown as a pie chart (d). Graphs show one point per donor with 756 a line representing the median. Comparisons across NK cell subsets were performed 757 using one-way ANOVA with Dunn's correction for multiple comparisons and between 758 conditions by Wilcoxon signed-rank test. *p <0.05, **p <0.01, ***p <0.001, ****p 759 < 0.0001.




Figure 4. High concentrations of inflammatory cytokines induced by EBOV GPstimulation in vitro.

Supernatants were collected from baseline (visit 0) and post-dose 2 (visit 2) PBMC after 18 hours stimulation with EBOV GP or medium alone and concentrations of IL-10 (a), IL-1 β (b), IFN- α 2 (c), GM-CSF (d), TNF- α (e) and IFN- γ (f) were determined by Luminex, n=70. Graphs show one point per donor with the median and IQR. Comparisons were performed using one-way ANOVA with Dunn's correction for multiple comparisons. *p <0.05, ***p <0.001, ****p <0.0001.

769

760

770




Figure 5. Myeloid accessory cell cytokine dependent NK cell activation.


774 Non-vaccinated control PBMC, purified NK cells or purified NK cells plus CD14⁺ 775 monocyte enriched population (mono) were stimulated with EBOV GP, n=5 (a-c). 776 PBMC were also left unstimulated or stimulated with EBOV GP in the presence of 777 blocking antibodies against IL-12 and IL-18 or appropriate isotype control (Iso.), n=16. NK cell function was analysed by flow cytometry. Graphs show CD56^{bright} IFN-y, 778 779 CD107a and CD25 expression (a-c), total NK cell CD25 MFI (d) or percentage (e) or 780 CD56^{bright} CD25 MFI (f) or percentage (g) and total NK cell CD107a (h) and IFN-y 781 expression (i). Concentrations of IL-18 in culture supernatant and intracellular IL-12 782 expression were determined by ELISA and flow cytometry respectively, the 783 relationship between IL-18 and total NK cell CD25 expression was determined by 784 Spearman's coefficient (j-l). IL-12(p40)⁺ B cells (CD19⁺), myeloid DC (mDC; CD19⁻ CD14⁻CD11c⁺), total CD14⁻ and total CD14⁺ cells were gated as per gating strategy in 785 786 Supplementary Figure 5a. Graphs show box and whisker plots with median, IQR (box) 787 and 10th-90th percentile (whiskers) or one point per donor. Comparisons were 788 performed using Wilcoxon signed-rank test and correlations were determined using Spearman's correlation. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. 789

790

791


- 792
- 793

794





798 The correlation between NK cell IFN-y secretion determined by intracellular staining 799 and IL-10 secretion measured by Luminex in response to EBOV GP (in baseline trial 800 samples) was determined by Spearman's coefficient, n=70 (a). Non-vaccinated control 801 PBMC were stimulated in the presence of blocking antibodies against IL-10R or 802 isotype control, n=16. Total NK cell IFN-y (b), CD107a (c) and CD25 (d) expression 803 was determined. Intracellular IL-10 was also measured by flow cytometry (gating 804 strategy as per Supplementary Figure 5a) in B cells (CD19⁺), myeloid DC (mDC; 805 CD14⁻CD11c⁺), total CD14⁻ and total CD14⁺ cells, NK cells (CD3⁻CD56⁺) and T cells 806 (CD3⁺) (e). The proportion of IL-10⁺ events per cell type determined by back-gating is 807 also shown as a pie chart (f). Graphs show box and whisker plots with median, IQR 808 (box) and 10th-90th percentile (whiskers). Comparisons were performed using Wilcoxon signed-rank test. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. 809



810

Figure 7. EBOV GP induced NK cell activation is dependent on interaction with TLR-4.

813 Non-vaccinated control PBMC were stimulated in the presence of blocking antibodies 814 against TLR-4 or isotype control, n=16. Supernatants were collected and 815 concentrations of IL-10, IL-1 β , GM-CSF, IFN- γ , IFN- α 2 and TNF- α were measured by 816 Luminex. Graphs show IL-10 concentration as one dot per donor (n=7 with values 817 below Luminex cut-off value of 10,000pg/ml) (a) and IL-1β, GM-CSF, IFN-γ, IFN-α2 818 and TNF- α as fold change between isotype control and TLR-4 blockade (b). 819 Expression of CD56^{bright} NK cell IFN-y (c) CD25 (d) were determined after 18 hours by 820 flow cytometry. Graphs show one point per donor (IL-10), median with IQR (remaining cytokines) or box and whisker plots with median, IQR (box) and 10th-90th percentile 821 822 (whiskers). Comparisons between conditions were performed using Wilcoxon signed-823 rank test. *p <0.05, ***p <0.001, ****p <0.0001.

Table 1: Vaccination schedule of each group and samples received (PBMC and corresponding serum).

	Samples received:			
Group (n)	Vaccine	Baseline	Post-dose 1	Post-dose 2
	schedule	(Visit 0)	(Visit 1)	(Visit 2)
Group 1 (n=15)	MVA, Ad26	Day 1	Day 29	Day 50
Group 2 (n=15)	MVA, Ad26	Day 1	Day 57	Day 78
Group 3 (n=14)	Ad26, MVA	Day 1	Day 29	Day 50
Group 4 (n=14)	Ad26, MVA	Day 1	Day 57	Day 78
Group 5 (n=12)	Ad26, MVA	Day 1	Day 15	Day 36